<SEC-DOCUMENT>0001144204-15-038979.txt : 20150625
<SEC-HEADER>0001144204-15-038979.hdr.sgml : 20150625
<ACCEPTANCE-DATETIME>20150625081236
ACCESSION NUMBER:		0001144204-15-038979
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20150625
FILED AS OF DATE:		20150625
DATE AS OF CHANGE:		20150625

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BIO BLAST PHARMA LTD.
		CENTRAL INDEX KEY:			0001596812
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36578
		FILM NUMBER:		15950651

	BUSINESS ADDRESS:	
		STREET 1:		37 DEREH MENACHEM BEGIN ST.
		STREET 2:		15TH FLOOR
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			6522042
		BUSINESS PHONE:		972 (0) 3 7326616

	MAIL ADDRESS:	
		STREET 1:		37 DEREH MENACHEM BEGIN ST.
		STREET 2:		15TH FLOOR
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			6522042
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>v414089_6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">UNITED STATES&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SECURITIES AND EXCHANGE COMMISSION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Washington, D.C. 20549</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 12pt">Form 6-K</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Report of Foreign Private Issuer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Pursuant to Rule 13a-16 or 15d-16</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">under the Securities Exchange Act of 1934</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">For the month of: June 2015 (Report No.
3)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Commission file number: 001-36578</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 12pt"><U>BIOBLAST
PHARMA LTD.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Translation of registrant's name into English)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">37 Dereh Menechem Begin St., 15<SUP>th</SUP>
Floor</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>Tel Aviv 6522042 Israel</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive offices)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant files or will
file annual reports under cover of Form 20-F or Form 40-F.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Form 20-F <FONT STYLE="font-family: Wingdings">x
</FONT>Form 40-F <FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark if the registrant is submitting the Form
6-K in paper as permitted by Regulations S-T Rule 101(b)(1):_____</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark if the registrant is submitting the Form
6-K in paper as permitted by Regulations S-T Rule 101(b)(7):_____</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>CONTENTS</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This Report of Foreign Private Issuer on
Form 6-K of the Registrant consists of the press release issued by the Registrant on June 25, 2015, announcing that it received
orphan drug designation from the European Commission for Cabaletta for the treatment of Oculopharyngeal Muscular Dystrophy, which
is attached hereto as Exhibit 99.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The first paragraph of the press release
attached to this Form 6-K of the Registrant is incorporated by reference into the registration statement on Form S-8 (File No.
333-203114) of the Registrant, filed with the Securities and Exchange Commission, to be a part thereof from the date on which this
report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Exhibit No.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0px">&nbsp;</TD>
    <TD STYLE="width: 96px; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">99.1</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Press Release issued by BioBlast Pharma Ltd. on June 25, 2015, announcing that it received orphan drug designation from the European Commission for Cabaletta for the treatment of Oculopharyngeal Muscular Dystrophy.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>SIGNATURES</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 45%; padding-bottom: 0pt">&nbsp;</TD>
    <TD STYLE="width: 6%; padding-bottom: 0pt">&nbsp;</TD>
    <TD STYLE="width: 49%; padding-bottom: 0pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>BioBlast Pharma Ltd. </U><BR>
        (Registrant)</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><BR>
        By <U>/s/ Colin Foster</U></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 0pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Name: Colin Foster</FONT><BR>
<FONT STYLE="font: 10pt Times New Roman, Times, Serif">Chief Executive Officer and President</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 0pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0pt"></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date: June 25, 2015</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>v414089_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"><IMG SRC="image_002.jpg" ALT="">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 11pt"><B>BioBlast
Pharma Receives Orphan Drug Designation From The European Commission For</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 11pt"><B>Cabaletta
For The Treatment Of Oculopharyngeal Muscular Dystrophy</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>TEL AVIV, Israel, June 25, 2015</B> &ndash; BioBlast Pharma
Ltd. (NasdaqGM: ORPN), a clinical-stage orphan disease-focused biotechnology company, announced today that it has been granted
Orphan Drug Designation by the&nbsp;European Commission for Cabaletta for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">BioBlast is starting a double-blind, placebo-controlled Phase
3 pivotal study across multiple clinical centers in the US and Canada in OPMD. The company recently announced positive clinical
signals observed in its ongoing HOPEMD study.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Cabaletta is a chemical chaperone that has been shown to prevent
pathological aggregation of proteins within cells in several diseases associated with abnormal cellular-protein aggregation, including
cell and animal models of Spinocerebellar Ataxia and other PolyA/PolyQ diseases, in addition to OPMD.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;This Orphan Drug Designation lays the foundation for
what we believe are very favorable conditions to address the needs of the many patients suffering from OPMD in Europe. It is yet
another step in BioBlast&rsquo;s efforts to create and capture value from our research and clinical work,&rdquo; stated Colin Foster,
President and Chief Executive Officer of&nbsp;BioBlast, who also noted that BioBlast has received Orphan Drug Designation for Cabaletta
in OPMD from the FDA in the U.S.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>About Orphan Drug Designation</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Orphan Drug Designation by the European Commission provides
regulatory and financial incentives for companies to develop and market therapies that treat a life-threatening or chronically
debilitating condition affecting no more than five in 10,000 persons in the European Union (EU), and where no satisfactory treatment
is available. In addition to a 10-year period of marketing exclusivity in the EU after product approval, orphan drug designation
provides incentives for companies seeking protocol assistance from the EMA during the product development phase, and direct access
to the centralized authorization procedure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>About Oculopharyngeal Muscular Dystrophy (OPMD)</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">OPMD is a rare inherited myopathy characterized by dysphagia
(difficulty in swallowing), the loss of muscle strength, and weakness in multiple parts of the body. Patients typically suffer
from severe dysphagia, ptosis (eye lid drooping), tongue atrophy, proximal lower limb weakness, dysphonia (altered and weak voice),
limitation in looking upward, facial muscle weakness and proximal upper limb weakness. The disease is most often diagnosed in the
fifth-sixth decade of life and progresses throughout the patient&rsquo;s life. As the dysphagia becomes more severe, patients become
malnourished, lose significant weight, become dehydrated and suffer from repeated incidents of aspiration pneumonia. These last
two are often the cause of death.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp; &nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">There is no medical treatment or, to our knowledge, potential
cure for OPMD. Current therapeutic strategies are confined to surgical interventions that have limited efficacy and need to be
repeated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>About BioBlast</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">BioBlast Pharma is a clinical-stage biotechnology company committed
to developing clinically meaningful therapies for patients with rare and ultra-rare genetic diseases. The company has a diverse
portfolio of product candidates with the potential to address unmet medical needs for incurable genetic orphan diseases.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The BioBlast platforms are based on deep understanding of the
disease-causing biological processes, and potentially offer solutions for several diseases that share the same biological pathology.
For more information please visit the Company's website, www.bioblast-pharma.com, the content of which is not incorporated herein
by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Forward-Looking Statements</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white">This press release contains
forward-looking statements within the meaning of the &ldquo;safe harbor&rdquo; provisions of the Private Securities Litigation
Reform Act of 1995 and other Federal securities laws. For example, we are using forward looking statements when we discuss that
our diverse portfolio of product candidates has the potential to address unmet medical needs for incurable genetic orphan diseases,
or that our platforms potentially address unmet medical needs and offer solutions for several diseases that share the same biological
pathology. In addition, historic results of scientific research and clinical and preclinical trials do not guarantee that the conclusions
of future research or trials would not suggest different conclusions or that historic results would not be interpreted differently
in light of additional research and clinical and preclinical trials results. Because such statements deal with future events and
are based on BioBlast Pharma&rsquo;s current expectations, they are subject to various risks and uncertainties and actual results,
performance or achievements of BioBlast Pharma could differ materially from those described in or implied by the statements in
this press release, including those discussed under the heading &ldquo;Risk Factors&rdquo; in BioBlast Pharma&rsquo;s Annual Report
on Form 20-F filed with the Securities and Exchange Commission (&ldquo;SEC&rdquo;) on March 31, 2015, and in any subsequent filings
with the SEC. Except as otherwise required by law, BioBlast Pharma disclaims any intention or obligation to update or revise any
forward-looking statements, which speak only as of the date hereof, whether as a result of new information, future events or circumstances
or otherwise.<IMG SRC="image_001.jpg" ALT="Description: http:||l2.yimg.com|bt|api|res|1.2|Vu_9Io6cZ7VEWep70Xb4Jw--|YXBwaWQ9eW5ld3M7cT04NQ--|https:||www.globenewswire.com|newsroom|ti?nf=MTQ1IzEwMDkyMTMwIzMyNDU1" STYLE="height: 3px; width: 3px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>CONTACT:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">U.S. Investor Contact</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Andrew McDonald</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Founding Partner</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">LifeSci Advisors, LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Andrew@LifeSciAdvisors.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">646-597-6987</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X``02D9)1@`!`0```0`!``#_VP!#``$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0'_
MVP!#`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0'_P``1"``V`/@#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#^_BH)@'"J
M"N0^.0&(.TG&,\'!Z'L?2L7Q+XIT#P?H.J>)?%&J6>AZ#H]K)>:GJ>HSI;VM
MK;Q#,CR2,<`D_)$@R\SX2,$D5^$?QJ_X*3_$CXU>/'^$7[+]S'X!T*4WRWWQ
M/U2!;G5X=*L9D6]\165JP>/3+&VB82(S&ZFE=H8]JB5RO/B\3A\'A<3C,77H
MX7"8/#U\7B\3B*GL:&'PN%HU,1B:]:KS04*=*A1K5)2<XJT+-I/72C0JXJM1
MPV'H3Q-?$5:5"AAZ</:U*U>M4A2HTH4U&;G.=6I3C&*A)N322;V_>UKB")_+
MEGCB<\!9)(HV(_A*HSACG''7/84KS(GWB0HW%V`&U$^9BSY!VJ%#$EL#`//'
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MEAJ6(K581A)RIQ47)?-/_!3_`/X*9>,?B5\2M:^!/P0\37&A?"SPG<7FC^(]
M5T:Y\J;Q_JZRFWOUGN(]P&@6+PO#:1J[?;&D:5@H3GY7_8?_`&J?B-^R_P"-
M]/UGPUJUU<>%+F^M)O%GA)[F2'2O$&G*0LL4T.647=M"\AL;H\QRD,0.2?SZ
M\+>#?&7B;5<:-X?UG5IE07<GV:QGN&*2A@99&2+"^8<2-(V?F#9/<^Q^&_M>
MD74<&I6D]G<6[%YK>[C:"1`-ZN9H)T5EC?;)L,H5)-OR$CBOZA2;FXJUM7&,
MG#GIQ2DVZU5S4>63A*5&K6E14H<E.+E.U.7X4HM+FM4<7[&2J5(3BY_6+^QB
MZDH0C5G_`,NXJ#E*T=815I/_`$!O!WB?2/&OA?0O%N@SK<Z/XBTVTU;3YU.0
M]O>0I*F2"=S+G8[?Q,K'O72U^??_``3'\7W7B[]DOP9]KF>9O#FI:OX8A\S.
M]+736MY+92#RJF&Z5T&3\KY&!P/T"W#)&#QC)P<?-TQZDGC`Y'&>HJ4TTFG=
M-73\G]WXI/ND/[U9M------IIII----:I;=K-NHJ/S/4$8(!ST&2!]XX'&?7
MGMDD4I<`G(P!U)X`P<'MZ]LY(P>AI@/HI`<C/Y=\CL>/4<TO?^1]3SQ^&/U]
MJ`"BH_,Z<'OGKD8(!X`.<9'(X.>*=O''<\9'H,9)_`<XZT`.HIF_H2,9..2!
M@G!`YZG![=,$'I3@<\CW_0X__50`M%%(S!02?\GM0`M%,W\9*D9`('KG/'U`
MP3GU'O4,ERD0W.K;1DL1M(&,>I!.<]AV/I1=+=I>K273JVEU77JDKO04I**<
MI.T8IRDWLHQ3E)OLDDV_3J]"S15<7`S@JP(.""5^7)PI)!(^8],9Z<XR*<9@
M`?D<G!(`"DL1V7YN2<\=C^!HOJDM;[63:>BEHTFOA:>]FGHWL%UWB[2Y7:47
M:7-RV=F[>]HV[)/=K<FHJ(2YW91E*XR#C.20!C!P>O)SP01VH\WYB-C8`SG*
MG/H`,YR??`'<TDTW9:M*_P!^VNU_[O,Y?W0NK-W5E?JNC:=ENVFFK)-]D[IN
M6BHO-`&2KCIQ@$\_[K$?K2>=SCRY.^3A<`#'/#'.<\`<\'@4<RLW=-)7NFFK
M:ZZ-Z:.S5T]U=:A?1.SM)2:O&2TBE)O5*UDUH[-[)-W2FHJ(R<XV,3SC[N#T
MQWX)SP,?C3E=6`.<9]2.OYTN:-[7U3<7ONDI/HE:THZW<6VDI-Z(NEN_ZT_^
M27W^MGT5$90`QP3@X`!&3[C)';GF@S*.&!7C/.WIZ\'I[D#-#E%:-NZ3;TEH
MDDVW:+LDG>[:3Z7::&[*]VE;?5:>;5[I:K5I+S):*B$H)(VMUX/!!&,Y!SW]
M^:*M)M)I732::U33U335]T&O9_<W^*37XG\RO_!6#]M*]\4_$6]_9]\(ZI):
M>#O`-W+#XJ6WE$<?B#Q9%''O@N?+?$ECH48DC17WQRS7#21)A3G\\OV/_&.F
MS_$WQ#H%S/%'JOC'P+K^@^'I9O\`73ZQ=O"T6G1R%B%DU/#*58'+6T2IM+L#
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MCTK1;/6-,N-2L#J4*2S7`UFQ1TG^R1J5C:V#J[996!``7VV]_P""27@[Q1J,
M'C3XF^.3\3_',-FFFVUAXCTRX'@#P]I<!+I8^&O#5M<!K:V6;#_O5+NR@2;\
M'/SW_P`$FOV\?!'C_6M?^&_Q#U"'P/\`$7Q'9Z;<VQNG@LO#?CC5[7?;7-]I
M1<K#8Z[<HT1N;!X[=+IR&B4NV*_H-8'IN*E00[J`'&Y\C:"-HS@@X`P37X7]
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M,OC6VFN;JVT6WB6<6\][>0QOADC+CKD`$'Y]^$/P#^(?Q_M_$/@?PSITL&B^
M*/)\&^+-9F5K6+1O#&K3J^KZI%=;&2>[M(+.*'R4)G=KC,91ANK^3>+.#^+?
M##Z:'A3A_"[,^+ZG#/'N#PF,SG#8WBK/N(\KQV7TIXVAQ=]>Q&:X[.<.\%@8
M4J.*B\2I/`U/JF)H5:,,5"E'^A,ASGAWC_Z,G'V+X^P.00XAX+Q5:A@)X'),
MIX>S+`XG&4\'B.'G0PV74<->MBI8F?LJ2IJ4:5.LZL(.D[?K7_P2E\-:CX<_
M8S\`W6HQA9/%-]K'BJV<MEIM/U$P164SO_$6BM$4'M&$'.,G\ROVS_VZ/VT_
M$/[>U_\`LC_L>:[H\%Q:V.F:3!:7$5E;J?$,<,UUX@N+_5;K>MO%9QK`F"AV
MB0G(R*_H>\%>%-!^&_@G0?!WAVTCL]!\'>'[/1=-M(8TBBBL=+L4A0+'&=BM
M*MJ97`)^>0DDMDG^,_X,_"O]H;]N']O[]IOXI?LS^/XOA5XET+7/$WB$>,KB
MXO;?[/#JNK7>FVFFPW-C!<-;2Z@VFA(9PN(/*.XX9@?]2Y>_4J-72YZG*Y63
M<%.2A.5DES3@H3GHKRG+17LOX-CS<L>:_-RQYFYNJW+ECS-U)).;<N9N6SOI
MI9O](OV/O^"BO[87A?\`;3L/V,?VP-(\/Z[K&LZC/H!U3P^L-QJ&AZY/`MQ9
MSKJ5I^XO=&FC#B=6CCEMF5%.-U?6T^O?M@^)O^"F::-X3^.W@.7]G3PY`DGB
M3X9:?XNLKK5X;&QLU&J6-UX26V%\NN0WDML\]X9_+ACS'MVRL*_)W_@D/=Z=
MX-_;S^-O@_\`:)\/'QQ^T)I.C>+M1TKXJ:EJ_P#PD,?A^^\(B1O%<D5S=/(U
MW/J\+VQL]2(#6B1,BRQ&8AN`_P""?WQ0U'1_B;_P40_;TG1M4U7X6_#;Q)K.
M@/?L]PM[KGCK7M9731<N0=[*NG0.5\S>\<0C4[0:IP6MEK;SM<9_6'\0?VD?
M@+\)=6BT+XE_%WP#X*UFYB>ZBTOQ!XBL+"^-NI5?--O+*)50=`7C0-C"\+EN
MUA^('A/6/`]Q\0?#GB#2-?\`"T>A:AK=MKVD7T%]ID]K96KW$DD5U;-+$5"Q
MG>0Y:,`A@#@C^27]B+]B+PQ^VM\%?VCOVQ_VMOB%XDUW59(_$,6AZI+KTT;Z
M5JFF:9<ZKJNL7TEQ,8EMO/GTZWL=,_=6T4*&/RDP$;(_X)R?&OQKX)_8!_X*
M/"7Q9JTOAOP1X,\,?\*\AO[ZYDL].U_Q1;>)=.NH-'-S(5MWOH[6PDN(+?RT
M9G4JN&#&>1^6GJ!W/P;_`&S?^"M?[7C_`!>\7?`/7O#DGAKX4Z@U_K]E<W&F
M:.MK97RZI=:7IMFERK-J$D=CI-Q-<HAB)Z[MN%K])O\`@F__`,%-/''[3/P/
M_:(U;XS:19:-XN_9]\-PZS?^*M'B^S:9JMEJNGZZ;5IX"SPV^JV5YHK&9=X6
M5)%DC4(&)_!SX`_LI?MAVG[!GQ<_::^#OQK_`.$*^&VI3:LGCGP'8Z]J?AS6
M?$V@^%X(8;W4Y;R".*TF*>>8[:U^U^?=++*$8`D-];?LY_%GX:>$/^",7[3=
M_P"#_!T?ACX@ZA?VOPZ\>^)]R&_\5ZAXC25=%OY+R0_:&:RM&OT6RER$FG9T
M5@[E6H::ZN]M&]-K@?;O_!"_XQ_'?X_77[1OC[XN?$7Q=XVT33;KPCI?A.'Q
M!J$UU86M]?S>);_6)[.-\QQ%[9=,A,:$+$JEB#O!'[)^+?VL_P!F?X?ZQ<>&
M_&7QR^&7AO6[(!;G2M4\6Z5;WML0"%6:)ISM<E2H5F5N.1G('\J'A_XZ^,OV
M./\`@DCX"T[P%+/X8^(W[5OQ#\:26_B2PD>VO]/\"Z'I]A8R&TN7,,\%](\H
MMDO8F;[*;R1@ZL0P\K_:X_8J^&_[+G[$7P=^)GCSQ%KGB7]J#X[ZU9>(IIYM
M;O;J"Q\-P:<MY?:8BW4OVJ\GA&I:?Y^IW0G_`-->1(W2(*9!P=]+6OHM27-)
MM6>A_:-#\7/AI-X)/Q)3QWX4;X?_`&<W/_"8#6;,:!Y:Y+D:B\JP/M49P&#]
M,(2:XCP=^U'^SO\`$.?5;;P1\9OAWXIN-"TR?6]7BTCQ%97;Z;I%IQ=:G=HD
MF8;6!L[Y6PBC&6RPS_,A^VK^SA\>]/\`^"8W[#MC\-/#WB;5?!'A+PGK^O?&
M[1/"MS?B=M7\2V6D7VEZKJNF6026^TVTBM]6MWG$;K9&51)$249/;?\`@G?H
M'_!//XR?!#]H#7?`G@SQQ\-_B5I/P%U/P?\`&73+K6Y;BZE\,ZI93M>>(?"M
MXUP8O^)E?:=(YC812:>^V-0H.47+;5O1;VW*/N3X5?\`!7;X>_%W]LKQ%^SM
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MXO\`L^=2-#FJ."S*IE_-+DE&FFZDDHQ;/I^"LFCQ%QAPOD<X>TI9MQ!E&`KP
M:;A+#XC,,-'$^UY4W[)8:&)=1V:4.9M66GQ5X3^-?[8GCSPIKGQ$\,7MM=^'
M/#1,VHQ@6L,WR0BYN8X;0F1KCRD'!WB/'&#GGVF#]K#5?'7[+?Q!\6EUT#QO
MH!MM#FO=,/D(;O4R#::G:('+VY9(Y/D9\[D<J@4`#YE^%>A_M5:_\($\!^`?
M#[V7A#QA+<ZB=;=K2SEN[.]6*.>$:B^9XH)(D6)GC!*)_J\/N-=+\>/AQ%^S
MS^SGX5^&]Q/#J'BKQKXHDUS79[,-Y+KIMDD0MEE<!Y8[.2X"K+.&CD8Y55WL
M&_R:X:X[\9<E\.N(>/(Y_P"-&(X8CX$<03\0<S\3\1B</D&-\0N*94<LX4AX
M9/$1P>/@Z$<THU\)CL!5=#EI>VG**G2Y_P"X<ZX6\/\`,N+<LX6JY3X>4\[?
MB9E4>%,%PA/#5LTH<)93"6,XEGQ?*A/ZDHUYY;4H1P>(525-2DY._,CZN_91
M^,6F1?"VSN?B;\1[$>(M;UJ]N+.U\0:S$+Y-,'V:&T4&8EDCEF662/)V_.1G
M()'W+]I@,/GF6W-NT:S&X\Q5B,)`82AF81^5@APYD"D$5^"_QL^`FC?"7X/?
M#+7;W4M1?Q]XOCEDO[?SY#9PV:V$<T%O;12,&B\EYHE(C`"RR.Q*G('M_P`?
M/'WCV7PO\$?@%H5Y>V.JZSX5T2\\3R0W\L5Q>3:DMO!I=I-=QR)<BWC0W-S/
M&74S`;5W`$5^Z>&_TGN*?"K@G/N#/$C@N.+S'PO\/O#&KD"RWB/%\09]Q5G_
M`!][.GD&0YYC<SISHT<\Q4L3B,?C)*4JF!P=!TY>UE0H2K_FG&/@UD/&W$>5
M<0\&\31HY?QGQ3QI#,98_*L-EV59%EO"D*E7-,PR58'ZM4Q>`H4L,J%"<E35
M>JU.2I1E-GZ6O\;?A##,;6;XB>%1.CK$T?\`:MN6$WR@(`C8)R1DAB.3SVKJ
M[_QIX6TBXTVWU3Q%I5E<:RK-I,=W>0P-J,1`8-;!GPZ-E#&XP&YQT-?B1^T?
M\$_!?PK\6?#GX=>$[O4=2\3:G9QS^*KJYNQ,)[^]OK*WMF6/=BVB)-S+"OE*
MQ\GYB<<>@_M@:+JOBGX[?#;X5^&+AH=0T;PMX?T"PD6=HVBN]4D51=!]Q>-H
M([65BYR^PL`02*^@Q'TOO$WA[`^)M'B;PRX3>?\``/%WASP/@\FX9XCS?'T,
MTX@X\Q',\CCC:F&PT)YAD^72PT*JP_-3I9A*K1K.%*E4J0\VCX`\&9MBN#:F
M3<99['*>*,DXSXFQ68YID6!PD\!E/"M&G3PV9.A3JU*D<+C<P=:I%2:JRR^5
M&KRJK4C3?ZRI\3/`$L6K7L7B[0&MM`:*+6KC^TX#%IDERSK;I<L'VQM,8950
ML06,9X`%5+WXM_#;3I+&&_\`''ANTEU)$N;!)=4LP;NWE*B&6$B1@PE!`5CL
M.0>"!7YB?M)_";PS^SS\&+3PGI%_>ZSX@^(/B.WO-=U"Z8;KU]"LSMB5/]9)
M:_:;EO+2;>[F21I`=RBO"?C9\#M.^%'PN^$&JWFH:O<>./'$%[=ZA`UU*UG9
M6-K!9/9Z?;02REX&1[^#8Z*BHRL%)&`8XZ^EQXP\#5>*L#C/";@ZIG/AYP9P
M?Q3X@WXPSJM@<@Q7%>?QP&$X;P$Z."3SC,\5@,3@)8:AAIT^3&RQLJ]2>%P\
M8UEPQX%<!\34\CQ=/COB%8/BSB7.,AX43X=PU/$9E1R7`1KXG,)T:V(E]3P=
M"O2QLZM7$TZB='ZK"DH5ZLI4OVYU'XG>`=)U6WT/5?&7AW3]6O&C:WT^XU&T
M2Z=)"1&#$92W[UN$.,G!SP37:75[;6L#7EW<06MHD9>6YEFCBA2(`8>6:8JB
M@@$@'D\$'U_"7]H#X*67PF\.?!ZXEUC6=4\?^,M.NK_Q-<7NHW,PBD0Z8+&*
MU$C^<B6]S?LL0'E@>4QP>*]U_:6\3>-/B'\1OAW^S;H.N7>G00:5X<M-<E6\
MEA?5-<U:%/->_D@9)IK;3K6WY@+;':?>4SO+>U0^F%Q/DU+Q+P_&_AEAL%GO
M"F,\,\IX7X;X>X@J9[BLYS_Q7IQKY!PYFV+K8?"X?+LRPU.M&IFDL/A<1'`T
MVL)RU<13E5EPS\`<EQT^$JW#O&U7$9)F]+C#&Y]G^9Y,\'2RO)N"L4\-F>;X
M3#.O7KXO"5ZW^S8)8FK:M4G3J1E2IN5./Z.)\</A(URUK_PL3PF)A*T2QMJU
ML&+*.<98#`;*GYC\P(R.@*_'GXL?`OP7H'QZ\$?!CP5+<W*26VCVFN75Q>R2
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MFGR&;3]/L)G*-Y/VI;6V,KQ(V#(,@;1G/RK7[MU6N>55<$ABP(`!W#8Q(.>"
M"!R""#T..H_T0:;32E*+:=I147..CUASQG%5$M:<I1:C44)6]U-?RS><=81Y
MIK:+:2?=2;<5RN/,I)M)QYHMV;/Y#_%OP5^"7P^\0ZKX+D^#V@:?K/AK6WAM
M?&&@ZOJ=KK3_`&2Y*VE]I^H+>_9UE`B$\,[1&-+B-6R0QK]1_#/_``4"_P"$
M:^"<OA!4\7^*OB''9W.C:/XF\4/9W-[/#-"R6FH:C/:D&ZNK"*0J`5WS2@,3
MD[C\Y_\`!0KP;J7[._Q5G\?>+O"FJZW\!OB)=R2:;XU\-6B7%]\./$]R8A/H
M7B*UBC*R>&6CVOHYC!F=WND4AU*CX9\0?M*?L_>`]/N-8\*:EJOQ3\0>4XT;
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M??M2?#[]I7X$1G0?#VB^#_B!X)EMM/\`B1X8TJ*..)]2NUF^S>)H7C)^T6NO
M/;W4ZR.-T-REQ`0-O/\`%?\`$+7_`!C\0_%FO^-_&%Q_:.N^);^?4]6NUC$9
M>65W<A0J[%ABC)1(E0*$X5>@/Z+?\$=OBUK_`,,_VT?!/AZVGO#I/Q/@N_!>
MNZ:DI6SN6E0W%A?W-NO#&QF=FC:1%=!-D*/F6O\`0OAKA;`\.9%PME'[G,<5
MPUPQDO#N'SK$TH8K&UL/@\HP.$QM7#XS$PEBZ=#.<50K8W&\M6*Q\Y4Y5%[&
ME0@OX\S[/L;G.:\08^4J^$P^?9[F.=5<OI8CDP_M,3F&)Q&$G5H8>4:<Y87"
M5*6$PL,1"4L+0@U2475J7_M!\7Z=KVI^$/$VF^&+JWTWQ#J&AZG8Z)?W*LUO
M8ZE=V<L%O<S!`SG[-(P=2,G<2!T(K^9GX5_\$<_^"@/P1F\7R_"7]J'PKX!;
MQ_&EMXMF\/WNM6,VK6RSW,H%TT>G2%GC>^N9HBK'#,X&"1N_J3B&`>2?F.0<
M?*3R5^7C(SS@D9)P:DKZ>+<;==+:MMO;5O=O0\!))62LELNB5VTEV2O9+HDD
MM$C\0_V5/^"1]Q^S!X"^-/B+_A85IX__`&F/B?X'UWP;H_Q!OTU!-&\,6NN0
MW`OC;1WRM?SW6HS3J^HZG.HNIO)0!0>%T/V(/^"55U\"_P!FW]HGX%_&WQ+H
M_B8_M"PVFFZY>^%8KC.G:98Z?=6]LT,UVD4QN+>\NGNXTC&POM.Y<$C]K**K
MG?D,_E8T+_@CE_P4!\#>'O&_[/?@;]I3P[I/[/GC_4/-\1(FH:E%:ZI`K`QW
M%_H@LY+M)'2.$:A;VC[;V9`[`J`1]Y_$#_@DT="_8)N_V1O@)XITS2_$WB7Q
MCH'BKQ]XV\0P/:GQ6]A#*E]:2FQB,D6GQEXDL+0J-D4;;B'8U^VE%'._+_,#
M^7/2O^",_P"WC=_#.S^`>K_M9Z!HOP4CO%NKGPCI=QKO]DN3B24M86VGQF\,
MARHANG6%G52[!`#7UO\`&7_@D=JL/[%GAG]DG]GKQ?H]C&WCV#X@?$?Q/XTA
MF2?QCK%G8_9K,.EG')Y=O:O-*;2W&8HHT^?$A`K]U:*.=^7W`?A-^U+_`,$D
M=>^,_P"QA^S;\#/"WB_1+#XE?LWZ#=Z5I^J7HNXM"\31ZQ;6J:^DABC:6WGN
M[BTAGAF9,;@P8C"@_&7CG_@B1^V/\8_"WP^U#XK?M*:3XJ\6^$[%?#FE^']>
MN]5U+1/!_A6$VHAL])G:'9-.[PI=2X48>WACW$Y"_P!4U%'.^R(<$W?74_%C
M]J3]E7_@HUJ7BCP[>?LL?M!Z#X)^'\'PR\,_#[4_`,TAM+**YTFPDLM4U5[6
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M,\\^'7@\^!/`OA7P=&_GKX>T:STPRHA5'>UC$;R`8&0Q)93D9QG![?,W[3O[
M-_C+XZ>(_!MWI>LZ1IVA^'(+J*:VO4F%RTM[=V4UQ/$\2$-F.S*+&YYW@]0N
M/MRBO"XT\)N#>/>!:?AOQ!A<<^$*=#(<*\MR[,<3ETZF%X:JY=6RC"U<504Z
MTL/0EE6#5:C&-..*C3E&NVIROW</\:9_PUQ//C#+J^$EGTZN8UOK.+P&&Q5*
M-;-88F&-JK#U.6G[2HL56<).3]FVN565G\*_M)_LS>+_`(TZOX"&D:QIEEH/
M@_3GL9+>^2Y\]KB:6Q::\@^1HV!@M!&%ZA@/E`))Y_\`:6_9*\3?$?Q-X<\>
M_#;6H='\1:%I=AI<T-U+<VF_^R2C:9>V,\*D1RP+YR21D`,74C/;]"J*^+XH
M^C-X3\8?Z^RSS+<XKUO$;,.$\TS_`!5'/L=AL5AL9P31^K\.U<BKT*=.>2?4
MZ,JL)+!\WME6J.=GRN/TF2>+_''#\^&99;C\+"GPIALZP>6X:K@,-7PF(PW$
M-=XC.*>:8>K&=/,)8UR=.I5JJG45&-.FFU2BY?EWIO[$OQ//Q*\+?$7Q7\0K
M/Q9J,&H6.I>))-1%Y)/NMKE)OL=J[Q[9H(X"8HR0!O!(RW->N1?LS^*;[]IR
M;XW:WJ6FW6A0ZDU]I5@!.U]!'%:+#9V[Q2H(X_)<.2PW#)..'8G[HHKS<G^B
MCX.9)3P]+"9;Q#5A1X]RCQ+J_P!H<4YOF<\=QCDF$J87`YIF-;'O$XC&:UZ^
M*KTJV(<,1C*TL14DY1@H]F8>-WB!F<IRQ6.RR#GPOF'!T?J>38'+U0R+,\7'
M%XC"X6."="EAI6A#"QJ4J*?U2$:#BTN9_$W[3G[./C'XZ>(/!5QI6L:7IVB>
M&8KP30WPF^TM/=W-E)+-&%C*,3%;.@R2.1C@9K/_`&A?V8_%GQF\9>`-1LM9
MTZQ\,>#;6VMY-.N_M"RS,+JP>Z>&&-&@;S+:P$8\TJ1N4#C-?=-%>WQ+]'+P
MRXLQ/'V+SK"Y]7K>)>;<)9OQ:Z?$6845C:O!57V^18'#J$']2RJG64*F*R[#
MM4<6Z:5244Y-^7D_BMQCD-'AJCEN)R^A'A+`YWE^2/\`LS#S="GQ#"=+-*];
MFJ-XC&UZ4Y4X8NHXU:,7^[U/A?XX_LQ^*?BW\5_!?BI=7TZW\(^%;?3K9].N
M%G-Y*;:\MKFXDB1$\HB06ZJ`QQD],+QR/[0/[)OCSQA\5K#XK_"S7[70=7":
M>URLTLUK-:W^GJ8H;R":)'9D>(A9$C&X$!LC!S^BU%</%'T8?"?BZGQ>LVR_
M.XXKC7BSA_C;-,SP'$&-P.:X/B#A;"+`9'B<CQ]"DJ^3TL#@G4H4J&%;BO:R
MJQJ1KQIU(]F2^,G'>03R#^S\=@5A^&\AS+AG+L%B<KPF*P4\FSBM#$YCA<?A
MJ_-#'/$XB$:LZN(O/F2^)7YOS/\``W[%GCWPM\9?"?Q-UKQM;>)GT_4(-9U^
M[O&NI=2N]0VSO.D9D0+)$CS;86D(.%QM&%)*_3"BOJ_#GP2\/?"S`9SEO"&6
MX[#X7/L[K<09@LQSG,LWKU<SKX6AA:];ZWF5;$XR;K1H*K5=;$UYU,15KU95
M/WBA#Y_C+C_BCCO%9;B^(,9AJU;*<MAE.">&R_"82%/`TZ\Z]*C[*A&G32I.
M?LZ:C"*C2A3@HI004R2,2+@X[X)&<$@CI^//KTHHK]9^Y^3U7S74^,_K_@/N
MGLULTVGHV<CXR\`^$OB'X9U3P=XVT+3/$OAC6K1[+4]&U2TCN;.ZAD4J^5DR
MT<@#,8IHF2:!CNBD1@#7X$?M'?\`!%CPCHDNK^-O@YXVAT+PO;075]/X2\4K
M?7C:?@JT%MI&I6EO<3R6T8!0+?LS!0@+/BBBA>[*,EI*,E.+N[IIMI+6W+=M
M<C4H.+<7%Q;37+'W/=C^[34-%:"DTVHJUE&Z5H[1^RD?B+XL^$"Z/XA/AN2Z
MLYI5EAA,R).(6\UI!C!Q(%_=#=@'(8X'`S^^W_!,3_@FGH?PP\1Z-^TQXS\1
MV'B;63I9'@31M.AO(K?1;J]4?VAJVJ/=)$MQJ`2-(;185DBC1G.Y#@$HI1C&
M,8QBDHQ2BDE:T5>R[M+F:5]EHK)))V6KLKMW;22;?=OJ^EWTTV/WK&.0!C!Q
M^@/X\$<GFEHHI@%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`444
04`%%%%`!1110`4444`?_V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X``02D9)1@`!`0```0`!``#_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+#`Q-#0T'R<Y/3@R/"XS-#+_
MVP!#`0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P``1"``#``,#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#W^BBB@#__
!V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
